Savara

OverviewSuggest Edit

Savara (also known as Savara Pharmaceuticals) is an orphan lung disease company. It offers Molgradex, a product that is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). The company also develops AeroVanc, an inhaled vancomycin that is in Phase III development stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.

TypePublic
Founded1995
HQAustin, TX, USMap
Websitesavarapharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)39(+19%)
Revenue (FY, 2020)$257 K
Share Price (Nov 2021)$1.1(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Savara

Matthew Pauls

Matthew Pauls

Chair and CEO
Dave Lowrance

Dave Lowrance

CFO
Badrul Chowdhury

Badrul Chowdhury

CMO
Dhaval Desai

Dhaval Desai

VP, Clinical Development
Anne Erickson

Anne Erickson

Senior Vice President, Chief of Staff
Kate McCabe

Kate McCabe

SVP, Legal Affairs
Show more

Savara Office Locations

Savara has offices in Austin and Hørsholm
Austin, TX, US (HQ)
6836 Bee Caves Rd Building 3, Suite 200
Hørsholm, DK
17 Slotsmarken
Show all (2)

Savara Financials and Metrics

Savara Revenue

Savara's revenue was reported to be $257 k in FY, 2020
USD

Net income (Q1, 2021)

(10.2m)

EBIT (Q1, 2021)

(10.4m)

Market capitalization (12-Nov-2021)

132.1m

Closing stock price (12-Nov-2021)

1.1

Cash (31-Mar-2021)

56.0m

EV

101.3m
Savara's current market capitalization is $132.1 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

128.0k257.0k

General and administrative expense

7.2m7.5m8.5m9.5m11.0m9.3m11.1m10.7m13.1m14.3m

R&D expense

5.8m8.1m12.9m19.4m28.3m20.8m18.5m37.2m38.8m35.0m

Operating expense total

12.9m15.6m21.4m28.9m39.2m30.1m29.6m70.0m79.0m49.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

45.0k94.0k256.0k

General and administrative expense

1.8m2.0m2.0m1.9m1.8m2.1m2.2m2.3m2.4m2.5m3.6m2.4m2.5m2.8m2.4m2.1m1.6m5.1m1.5m1.8m2.5m3.1m2.8m4.2m2.8m3.0m3.1m5.4m2.8m

R&D expense

1.3m2.1m2.2m2.1m1.7m3.4m3.1m4.3m4.8m5.4m6.0m7.7m7.3m7.9m7.8m5.1m1.4m4.2m5.0m8.5m9.3m9.5m10.0m10.5m9.6m13.2m6.1m5.6m7.6m

Operating expense total

3.2m4.0m4.3m4.0m3.5m5.6m5.3m6.5m7.2m7.9m9.6m10.1m9.8m10.7m10.2m7.2m3.0m9.3m6.5m10.3m11.8m12.7m12.9m22.2m12.4m16.2m9.3m11.0m10.4m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

43.6m22.5m25.7m35.8m23.1m8.5m22.1m24.3m49.8m22.9m

Accounts Receivable

1.7m1.6m1.7m

Prepaid Expenses

256.3k646.6k1.1m1.1m1.3m903.0k3.6m723.0k431.0k1.0m

Current Assets

51.8m37.2m45.5m58.4m42.3m12.2m97.9m113.3m124.1m85.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

42.0m32.8m35.1m30.0m26.1m21.4m45.0m30.2m29.8m26.4m26.0m27.9m21.2m32.2m23.5m24.5m20.5m7.8m61.1m19.8m22.1m23.6m24.9m25.7m16.8m17.8m34.5m47.1m35.2m56.0m

Accounts Receivable

1.5m1.7m1.4m1.6m1.7m527.0k

Prepaid Expenses

776.2k560.8k292.7k484.5k700.7k511.2k684.1k542.4k992.5k1.1m984.8k675.0k1.4m1.5m1.2m746.0k1.3m388.0k2.5m2.2m2.6m2.7m2.7m631.0k541.0k393.0k508.0k1.0m1.1m2.1m

Current Assets

42.7m39.0m47.3m44.3m41.6m32.5m54.1m49.9m50.6m47.6m44.1m50.6m44.8m51.4m38.2m35.8m28.3m8.2m63.7m55.5m87.6m77.4m114.7m107.5m114.2m108.3m107.4m102.6m96.3m194.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(13.3m)(15.6m)(21.5m)(28.7m)(39.8m)(36.1m)(29.8m)(61.5m)(78.2m)(49.6m)

Depreciation and Amortization

37.6k90.0k39.5k85.0k146.0k99.0k363.0k526.0k1.0m693.0k

Accounts Payable

196.5k120.5k2.5m2.5m1.2m(2.0m)159.0k

Cash From Operating Activities

(13.5m)(13.9m)(17.8m)(24.6m)(32.9m)(37.3m)(28.2m)(39.3m)(45.1m)(39.8m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(7.3m)(10.9m)(4.2m)(8.4m)(11.6m)(5.6m)(10.5m)(15.8m)(6.4m)(13.5m)(21.4m)(9.6m)(19.8m)(29.7m)(11.2m)(21.9m)(30.1m)(5.9m)(16.5m)(23.3m)(26.8m)(38.4m)(51.0m)(12.1m)(34.1m)(46.5m)(15.4m)(24.8m)(35.9m)(10.2m)

Depreciation and Amortization

20.2k28.7k30.2k66.9k77.6k9.8k18.7k28.7k11.5k34.0k59.8k30.0k67.0k105.0k32.0k61.0k86.0k11.0k181.0k272.0k107.0k260.0k387.0k307.0k539.0k772.0k242.0k455.0k574.0k47.0k

Accounts Payable

261.1k374.8k(533.5k)46.6k127.5k563.4k523.7k1.5m(62.0k)(200.4k)1.6m733.0k2.4m3.5m(1.1m)668.0k(2.9m)(127.0k)1.8m143.0k(554.0k)(444.0k)1.4m

Cash From Operating Activities

(7.0m)(10.4m)(4.4m)(7.4m)(10.6m)(4.5m)(9.2m)(12.9m)(6.3m)(13.3m)(18.6m)(7.3m)(15.9m)(24.1m)(11.3m)(19.0m)(29.9m)(3.2m)(10.5m)(18.8m)(9.7m)(20.0m)(28.8m)(10.9m)(23.8m)(35.2m)(13.1m)(20.8m)(27.5m)(9.6m)
show all
USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

Savara Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

Learn more about our premium products
SecurityScorecard logo

Savara Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Savara Online and Social Media Presence

Savara's Trends

Embed Graph

Savara News and Updates

December 10, 2020

Savara Provides Pipeline and Business Update

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial
November 24, 2020

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences
November 11, 2020

Savara to Present at the Jefferies Virtual London Healthcare Conference

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST

 Savara Frequently Asked Questions

  • When was Savara founded?

    Savara was founded in 1995.

  • Who are Savara key executives?

    Savara's key executives are Matthew Pauls, Dave Lowrance and Badrul Chowdhury.

  • How many employees does Savara have?

    Savara has 39 employees.

  • What is Savara revenue?

    Latest Savara annual revenue is $257 k.

  • What is Savara revenue per employee?

    Latest Savara revenue per employee is $6.6 k.

  • Who are Savara competitors?

    Competitors of Savara include NanoViricides, Lung Biotechnology and Nanomi.

  • Where is Savara headquarters?

    Savara headquarters is located at 6836 Bee Caves Rd Building 3, Suite 200, Austin.

  • Where are Savara offices?

    Savara has offices in Austin and Hørsholm.

  • How many offices does Savara have?

    Savara has 2 offices.